首页 > 最新文献

British Journal of Dermatology最新文献

英文 中文
Management of dupilumab-related ocular surface disorders. 杜比鲁单抗相关眼表疾病的治疗。
IF 3.5 1区 医学 Q1 DERMATOLOGY Pub Date : 2024-11-18 DOI: 10.1093/bjd/ljae350
Tina Felfeli, Aaron M Drucker
{"title":"Management of dupilumab-related ocular surface disorders.","authors":"Tina Felfeli, Aaron M Drucker","doi":"10.1093/bjd/ljae350","DOIUrl":"10.1093/bjd/ljae350","url":null,"abstract":"","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":"857-858"},"PeriodicalIF":3.5,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142124873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effective therapy of simvastatin compound ointment in LSS variants-induced palmoplantar keratoderma. 辛伐他汀复方软膏对 LSS 变体引起的掌跖角化症的有效治疗。
IF 11 1区 医学 Q1 DERMATOLOGY Pub Date : 2024-11-16 DOI: 10.1093/bjd/ljae451
Yumeng Wang, Anqi Zhao, Haisheng Huang, Yujuan Zhai, Yeqiang Liu, Yifan Yang, Chaolan Pan, Qiaoyu Cao, Wei He, Qin Zeng, Qin Yan, Min Li, Ming Li
{"title":"Effective therapy of simvastatin compound ointment in LSS variants-induced palmoplantar keratoderma.","authors":"Yumeng Wang, Anqi Zhao, Haisheng Huang, Yujuan Zhai, Yeqiang Liu, Yifan Yang, Chaolan Pan, Qiaoyu Cao, Wei He, Qin Zeng, Qin Yan, Min Li, Ming Li","doi":"10.1093/bjd/ljae451","DOIUrl":"https://doi.org/10.1093/bjd/ljae451","url":null,"abstract":"","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":11.0,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142643375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Crosstalk Between Fibroblasts and Immune Cells in keloids. 瘢痕疙瘩中成纤维细胞与免疫细胞之间的相互关系
IF 11 1区 医学 Q1 DERMATOLOGY Pub Date : 2024-11-16 DOI: 10.1093/bjd/ljae449
Junxian Wen, Yingrou Tan, Yong Yao Chun, Timothy T Y Tan, Hong Liang Tey
{"title":"Crosstalk Between Fibroblasts and Immune Cells in keloids.","authors":"Junxian Wen, Yingrou Tan, Yong Yao Chun, Timothy T Y Tan, Hong Liang Tey","doi":"10.1093/bjd/ljae449","DOIUrl":"https://doi.org/10.1093/bjd/ljae449","url":null,"abstract":"","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":11.0,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Localised multiple spiradenomas are caused by somatic mosaicism in ALPK1 hotspot mutation. 局部多发性螺旋状腺瘤是由 ALPK1 热点突变的体细胞嵌合引起的。
IF 11 1区 医学 Q1 DERMATOLOGY Pub Date : 2024-11-15 DOI: 10.1093/bjd/ljae448
Yui Hirano-Lotman, Yoshihiro Ishida, Hiromi Doi, Seishi Ogawa, Kenji Kabashima
{"title":"Localised multiple spiradenomas are caused by somatic mosaicism in ALPK1 hotspot mutation.","authors":"Yui Hirano-Lotman, Yoshihiro Ishida, Hiromi Doi, Seishi Ogawa, Kenji Kabashima","doi":"10.1093/bjd/ljae448","DOIUrl":"https://doi.org/10.1093/bjd/ljae448","url":null,"abstract":"","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":11.0,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phase 2 Trial of Topical Application of the Hedgehog Inhibitor Patidegib in Patients With Gorlin Syndrome. 戈林综合征患者局部应用刺猬抑制剂 Patidegib 的 2 期试验。
IF 11 1区 医学 Q1 DERMATOLOGY Pub Date : 2024-11-15 DOI: 10.1093/bjd/ljae444
John T Lear, Catherine A Harwood, Zeeshaan Hasan, Jonathan Kentley, Jason Thomson, Andre Khoo, Alix Alderman, Mark DeSouza, Ervin H Epstein, Gerd G Kochendoerfer, Jean Y Tang

Background: Patients with Gorlin (basal cell nevus) syndrome (GS) have numerous phenotypic abnormalities due to over-activity of the hedgehog (HH) signaling pathway, most commonly due to a heritable mutation in the PTCH1 gene, which encodes a major inhibitor of this pathway. HH inhibitors (HHi) taken orally can reverse some of the manifestations, most prominent of which is the development of numerous cutaneous basal cell carcinomas (BCCs). In order to improve the benefit:risk ratio, we have developed a gel containing a small cyclopamine-derived molecule that can be applied topically in expectation that this mode of delivery can reduce the burden of BCCs without producing the systemic adverse effects that cause patients to stop treatment with oral HHis.

Objectives: This study attempts to determine whether or not Patidegib Topical Gel, 2% or 4%, can accumulate in high enough concentrations to have local anti-BCC efficacy but not so high that systemic drug levels produce the adverse effects that are typical of oral HHi treatment.

Methods: We conducted a small, randomized, double blinded Phase 2A trial at two sites in the United Kingdom to assess the clinical and molecular efficacy and adverse effects of 6 months of twice daily application of Patidegib Topical Gel to the entire face as well as to treatment-targeted surgically-eligible BCCs at other anatomical sites.

Results: Post hoc analyses suggested that Patidegib Topical Gel reduced the number of new surgically-eligible BCCs and the level of HH signaling with minimal adverse effects.

Conclusions: Patidegib Topical Gel warrants further clinical development.

背景:戈林(基底细胞痣)综合征(GS)患者由于刺猬(HH)信号通路过度活跃而出现多种表型异常,最常见的原因是 PTCH1 基因发生遗传性突变,而 PTCH1 基因编码该通路的一个主要抑制因子。口服 HH 抑制剂(HHi)可逆转某些表现,其中最突出的表现是出现大量皮肤基底细胞癌(BCC)。为了提高收益风险比,我们开发了一种含有环丙胺衍生小分子的凝胶,可以局部涂抹,期望这种给药方式可以减轻 BCC 的负担,而不会产生导致患者停止口服 HHis 治疗的全身性不良反应:本研究试图确定帕替吉布外用凝胶(2%或4%)是否能蓄积足够高的浓度,以产生局部抗BCC疗效,但又不会过高,以至于全身药物水平产生口服HHi治疗的典型不良反应:我们在英国的两个地点进行了一项小型、随机、双盲的 2A 期试验,以评估帕替吉布局部凝胶每天两次用于整个面部以及其他解剖部位符合手术条件的 BCC 6 个月的临床和分子疗效及不良反应:结果:事后分析表明,Patidegib局部凝胶减少了新的符合手术条件的BCC数量和HH信号水平,且不良反应极小:结论:Patidegib局部凝胶值得进一步临床开发。
{"title":"Phase 2 Trial of Topical Application of the Hedgehog Inhibitor Patidegib in Patients With Gorlin Syndrome.","authors":"John T Lear, Catherine A Harwood, Zeeshaan Hasan, Jonathan Kentley, Jason Thomson, Andre Khoo, Alix Alderman, Mark DeSouza, Ervin H Epstein, Gerd G Kochendoerfer, Jean Y Tang","doi":"10.1093/bjd/ljae444","DOIUrl":"https://doi.org/10.1093/bjd/ljae444","url":null,"abstract":"<p><strong>Background: </strong>Patients with Gorlin (basal cell nevus) syndrome (GS) have numerous phenotypic abnormalities due to over-activity of the hedgehog (HH) signaling pathway, most commonly due to a heritable mutation in the PTCH1 gene, which encodes a major inhibitor of this pathway. HH inhibitors (HHi) taken orally can reverse some of the manifestations, most prominent of which is the development of numerous cutaneous basal cell carcinomas (BCCs). In order to improve the benefit:risk ratio, we have developed a gel containing a small cyclopamine-derived molecule that can be applied topically in expectation that this mode of delivery can reduce the burden of BCCs without producing the systemic adverse effects that cause patients to stop treatment with oral HHis.</p><p><strong>Objectives: </strong>This study attempts to determine whether or not Patidegib Topical Gel, 2% or 4%, can accumulate in high enough concentrations to have local anti-BCC efficacy but not so high that systemic drug levels produce the adverse effects that are typical of oral HHi treatment.</p><p><strong>Methods: </strong>We conducted a small, randomized, double blinded Phase 2A trial at two sites in the United Kingdom to assess the clinical and molecular efficacy and adverse effects of 6 months of twice daily application of Patidegib Topical Gel to the entire face as well as to treatment-targeted surgically-eligible BCCs at other anatomical sites.</p><p><strong>Results: </strong>Post hoc analyses suggested that Patidegib Topical Gel reduced the number of new surgically-eligible BCCs and the level of HH signaling with minimal adverse effects.</p><p><strong>Conclusions: </strong>Patidegib Topical Gel warrants further clinical development.</p>","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":11.0,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Interactive effect of genetic and environmental risk factors on Psoriasis: current evidence and future directives. 遗传和环境风险因素对银屑病的交互影响:现有证据和未来方向。
IF 11 1区 医学 Q1 DERMATOLOGY Pub Date : 2024-11-15 DOI: 10.1093/bjd/ljae450
Nidhi Singh, Tamara Schikowski
{"title":"Interactive effect of genetic and environmental risk factors on Psoriasis: current evidence and future directives.","authors":"Nidhi Singh, Tamara Schikowski","doi":"10.1093/bjd/ljae450","DOIUrl":"https://doi.org/10.1093/bjd/ljae450","url":null,"abstract":"","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":11.0,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-world data confirms limited efficacy of dual anti-PD-1 and CTLA-4 immune checkpoint blockade in acral lentiginous melanoma. 真实世界的数据证实了抗PD-1和CTLA-4双重免疫检查点阻断疗法对渐冻人黑色素瘤的有限疗效。
IF 11 1区 医学 Q1 DERMATOLOGY Pub Date : 2024-11-15 DOI: 10.1093/bjd/ljae445
David X Zheng, Russell W Jenkins
{"title":"Real-world data confirms limited efficacy of dual anti-PD-1 and CTLA-4 immune checkpoint blockade in acral lentiginous melanoma.","authors":"David X Zheng, Russell W Jenkins","doi":"10.1093/bjd/ljae445","DOIUrl":"https://doi.org/10.1093/bjd/ljae445","url":null,"abstract":"","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":11.0,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Haematogenous seeding in mycosis fungoides and Sézary syndrome: Current evidence and clinical implications. 真菌病和塞扎里综合征中的血源性播种:现有证据和临床意义。
IF 11 1区 医学 Q1 DERMATOLOGY Pub Date : 2024-11-15 DOI: 10.1093/bjd/ljae441
Robert Gniadecki, Emmanuella Guenova, Christiane Querfeld, Jan P Nicolay, Julia Scarisbrick, Lubomir Sokol

Cutaneous T-cell lymphomas (CTCLs) are a heterogeneous group of diseases characterised by abnormal neoplastic T-cell growth in the skin. Mycosis fungoides (MF), the most common CTCL, manifests as erythematous skin patches and/or plaques, tumours or erythroderma. The disease may involve blood, lymph nodes and rarely viscera. Sézary syndrome (SS) is a unique leukaemia/lymphoma syndrome related to MF, which presents with blood and skin involvement at diagnosis. The pathogenesis of MF/SS is not fully elucidated. The presence of skin lesions at distant sites underpins a hypothesis that MF/SS lesions may develop through haematogenous seeding. Phenotypic similarities between malignant and normal T-cells led to the notion that disease-initiating mutations occur in specific subtypes of mature T-cells, which are responsible for most CTCLs. However, this mature T-cell precursor model is not always consistent with clinical observations and research on MF/SS pathogenesis. Here, we review evidence supporting an alternative model of pathogenesis for MF/SS involving haematogenous seeding as a key process responsible for the initiation and progression of the disease. According to this hypothesis, malignant transformation occurs at an early stage of T-cell development (probably in bone marrow or thymus), yielding circulating neoplastic T-cells which colonise the skin where the microenvironment is most permissive for proliferation and evolution. These mutated precursor cells seed the skin where they find a suitable niche to develop into clinically perceptible disease. Subsequently, malignant T-cells can re-enter the bloodstream, re-seed pre-existing lesions and seed new areas of the skin, causing synchronous and convergent changes in the transcriptomic profile of lesions and tumours, and clinical disease progression - 'consecutive haematogenous seeding' captures this temporal phenomenon. This model radically changes the current understanding of CTCL pathogenesis, transforming it from a primarily cutaneous disease with secondary involvement of blood, to a systemic disease, where the spread of malignant cells through the blood to the skin is not a phenomenon of advanced disease but is an essential component of pathogenesis. This understanding of MF/SS could have several clinical implications, including standardising our approach to assessing blood tumour burden, potential advances in prognosis and monitoring, and investigating combination treatments to improve patient outcomes.

皮肤 T 细胞淋巴瘤(CTCLs)是一类异质性疾病,其特征是皮肤中出现异常的肿瘤性 T 细胞生长。放线菌病(MF)是最常见的皮肤 T 细胞淋巴瘤,表现为皮肤红斑和/或斑块、肿瘤或红斑。该病可累及血液、淋巴结,很少累及内脏。塞扎里综合征(SS)是与 MF 相关的一种独特的白血病/淋巴瘤综合征,确诊时表现为血液和皮肤受累。MF/SS 的发病机制尚未完全阐明。远处皮肤病变的出现支持了一种假设,即 MF/SS 病变可能是通过血源性播种形成的。恶性 T 细胞和正常 T 细胞在表型上的相似性使人们认为,疾病的诱发突变发生在特定亚型的成熟 T 细胞中,它们是大多数 CTCL 的罪魁祸首。然而,这种成熟 T 细胞前体模型并不总是与 MF/SS 发病机制的临床观察和研究相一致。在此,我们回顾了支持 MF/SS 发病机制替代模型的证据,该模型将血源性播种作为疾病发生和发展的关键过程。根据这一假说,恶性转化发生在 T 细胞发育的早期阶段(可能在骨髓或胸腺中),产生循环肿瘤性 T 细胞,这些细胞在微环境最有利于增殖和进化的皮肤上定植。这些变异的前体细胞在皮肤上播种,并在那里找到合适的生长环境,发展成临床上可感知的疾病。随后,恶性 T 细胞会再次进入血液,重新播种已有的病灶,并播种新的皮肤区域,导致病灶和肿瘤的转录组发生同步和趋同的变化,并导致临床疾病进展--"连续血源性播种 "捕捉到了这一时间现象。这一模型从根本上改变了目前对 CTCL 发病机制的认识,将其从一种主要是皮肤病、继发于血液的疾病转变为一种全身性疾病,在这种疾病中,恶性细胞通过血液扩散到皮肤并不是疾病晚期的一种现象,而是发病机制的一个重要组成部分。对 MF/SS 的这种认识可能会产生一些临床影响,包括使我们评估血液肿瘤负荷的方法标准化、预后和监测方面的潜在进步以及研究改善患者预后的综合治疗方法。
{"title":"Haematogenous seeding in mycosis fungoides and Sézary syndrome: Current evidence and clinical implications.","authors":"Robert Gniadecki, Emmanuella Guenova, Christiane Querfeld, Jan P Nicolay, Julia Scarisbrick, Lubomir Sokol","doi":"10.1093/bjd/ljae441","DOIUrl":"https://doi.org/10.1093/bjd/ljae441","url":null,"abstract":"<p><p>Cutaneous T-cell lymphomas (CTCLs) are a heterogeneous group of diseases characterised by abnormal neoplastic T-cell growth in the skin. Mycosis fungoides (MF), the most common CTCL, manifests as erythematous skin patches and/or plaques, tumours or erythroderma. The disease may involve blood, lymph nodes and rarely viscera. Sézary syndrome (SS) is a unique leukaemia/lymphoma syndrome related to MF, which presents with blood and skin involvement at diagnosis. The pathogenesis of MF/SS is not fully elucidated. The presence of skin lesions at distant sites underpins a hypothesis that MF/SS lesions may develop through haematogenous seeding. Phenotypic similarities between malignant and normal T-cells led to the notion that disease-initiating mutations occur in specific subtypes of mature T-cells, which are responsible for most CTCLs. However, this mature T-cell precursor model is not always consistent with clinical observations and research on MF/SS pathogenesis. Here, we review evidence supporting an alternative model of pathogenesis for MF/SS involving haematogenous seeding as a key process responsible for the initiation and progression of the disease. According to this hypothesis, malignant transformation occurs at an early stage of T-cell development (probably in bone marrow or thymus), yielding circulating neoplastic T-cells which colonise the skin where the microenvironment is most permissive for proliferation and evolution. These mutated precursor cells seed the skin where they find a suitable niche to develop into clinically perceptible disease. Subsequently, malignant T-cells can re-enter the bloodstream, re-seed pre-existing lesions and seed new areas of the skin, causing synchronous and convergent changes in the transcriptomic profile of lesions and tumours, and clinical disease progression - 'consecutive haematogenous seeding' captures this temporal phenomenon. This model radically changes the current understanding of CTCL pathogenesis, transforming it from a primarily cutaneous disease with secondary involvement of blood, to a systemic disease, where the spread of malignant cells through the blood to the skin is not a phenomenon of advanced disease but is an essential component of pathogenesis. This understanding of MF/SS could have several clinical implications, including standardising our approach to assessing blood tumour burden, potential advances in prognosis and monitoring, and investigating combination treatments to improve patient outcomes.</p>","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":11.0,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emerging Challenges in Global Health Dermatology: measuring impact and sustainability. 全球健康皮肤病学的新挑战:衡量影响和可持续性。
IF 11 1区 医学 Q1 DERMATOLOGY Pub Date : 2024-11-15 DOI: 10.1093/bjd/ljae435
Morvarid Zehtab, L Claire Fuller, Wendemagegn Enbiale, Karolyn A Wanat, Luca Borradori, Henry W Lim, Esther E Freeman
{"title":"Emerging Challenges in Global Health Dermatology: measuring impact and sustainability.","authors":"Morvarid Zehtab, L Claire Fuller, Wendemagegn Enbiale, Karolyn A Wanat, Luca Borradori, Henry W Lim, Esther E Freeman","doi":"10.1093/bjd/ljae435","DOIUrl":"https://doi.org/10.1093/bjd/ljae435","url":null,"abstract":"","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":11.0,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring the driver events of eccrine poromas and porocarcinomas: A retrospective, cross-institutional study of 54 cases. 探究非肾孔瘤和孔癌的驱动因素:对 54 例病例的跨机构回顾性研究。
IF 11 1区 医学 Q1 DERMATOLOGY Pub Date : 2024-11-15 DOI: 10.1093/bjd/ljae447
Mark J Arends, Martin Del Castillo Velasco-Herrera, Saamin Cheema, Kim Wong, Jacqueline M Boccacino, Ian Vermes, Kirsty Roberts, Elizabeth Anderson, Michiel P J van der Horst, Nicolas de Saint Aubain, Ahmed K Alomari, Carlos Monteagudo, Steven D Billings, Derek Frew, Emily Clarke, William Merchant, Neil Rajan, Peter Ferguson, Carolin Mogler, Ingrid Ferreira, Thomas Brenn, Louise van der Weyden, David J Adams
{"title":"Exploring the driver events of eccrine poromas and porocarcinomas: A retrospective, cross-institutional study of 54 cases.","authors":"Mark J Arends, Martin Del Castillo Velasco-Herrera, Saamin Cheema, Kim Wong, Jacqueline M Boccacino, Ian Vermes, Kirsty Roberts, Elizabeth Anderson, Michiel P J van der Horst, Nicolas de Saint Aubain, Ahmed K Alomari, Carlos Monteagudo, Steven D Billings, Derek Frew, Emily Clarke, William Merchant, Neil Rajan, Peter Ferguson, Carolin Mogler, Ingrid Ferreira, Thomas Brenn, Louise van der Weyden, David J Adams","doi":"10.1093/bjd/ljae447","DOIUrl":"https://doi.org/10.1093/bjd/ljae447","url":null,"abstract":"","PeriodicalId":9238,"journal":{"name":"British Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":11.0,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
British Journal of Dermatology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1